NASDAQ:ABCL AbCellera Biologics Q1 2025 Earnings Report $2.43 -0.01 (-0.41%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$2.41 -0.02 (-0.82%) As of 09:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast AbCellera Biologics EPS ResultsActual EPSN/AConsensus EPS -$0.17Beat/MissN/AOne Year Ago EPSN/AAbCellera Biologics Revenue ResultsActual RevenueN/AExpected Revenue$7.12 millionBeat/MissN/AYoY Revenue GrowthN/AAbCellera Biologics Announcement DetailsQuarterQ1 2025Date5/8/2025TimeAfter Market ClosesConference Call DateThursday, May 8, 2025Conference Call Time5:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Remove Ads AbCellera Biologics Earnings Headlines3 Hot Stock Upgrades as Analysts Look Ahead to Q2 EarningsAnalysts are upgrading Netflix, Meta Platforms, and Snowflake after their CQ4 2024 earnings reports and leading their markets to new highs.March 19, 2025 | marketbeat.comNetflix's 'Black Mirror' Returns With Grim Warning About Life Trapped Behind Endless PaywallsApril 16 at 8:10 AM | benzinga.comCould this be the start of AI’s Second Wind?We're living in unprecedented times. Most people think it's too late to get into AI right now … That the biggest profits are already off the table.April 16, 2025 | Weiss Ratings (Ad)Cautious Outlook on Netflix: Hold Rating Amidst Ambitious Targets and Market AlignmentApril 16 at 5:56 AM | tipranks.comNetflix Earnings Preview: Can Netflix Deliver Big Again?April 16 at 3:51 AM | talkmarkets.comWhy Is Netflix (NFLX) Stock Soaring TodayApril 15 at 11:46 PM | msn.comSee More Netflix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AbCellera Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AbCellera Biologics and other key companies, straight to your email. Email Address About AbCellera BiologicsAbCellera Biologics (NASDAQ:ABCL) builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.View AbCellera Biologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB? Upcoming Earnings Netflix (4/17/2025)American Express (4/17/2025)Blackstone (4/17/2025)Infosys (4/17/2025)Marsh & McLennan Companies (4/17/2025)Charles Schwab (4/17/2025)Taiwan Semiconductor Manufacturing (4/17/2025)UnitedHealth Group (4/17/2025)HDFC Bank (4/18/2025)Progressive (4/18/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
